{Reference Type}: Journal Article
{Title}: Prevalence of pathogenic or likely pathogenic germline variants in cancer predisposition genes among selected patients with lung adenocarcinoma: The GERMLUNG study.
{Author}: Arrieta O;Caballé-Pérez E;Hernández-Pedro N;Romero-Nuñez E;Lucio-Lozada J;Castillo-Ruiz C;Acevedo-Castillo K;María Álvarez-Gómez R;Molina-Garay C;Jiménez-Olivares M;Carrillo-Sánchez K;Cristina Mendoza-Caamal E;Cardona AF;Remon J;Alaez-Verson C;
{Journal}: Lung Cancer
{Volume}: 194
{Issue}: 0
{Year}: 2024 Aug 28
{Factor}: 6.081
{DOI}: 10.1016/j.lungcan.2024.107864
{Abstract}: <B>BACKGROUND: </B>Pathogenic or likely pathogenic germline variants (PGVs) in cancer predisposition genes may play a role in lung cancer (LC) susceptibility. However, determining an eligible population for genetic testing remains uncertain. This study aimed to assess the prevalence of PGVs in a selected cohort of individuals with lung adenocarcinoma.<BR><B>METHODS: </B>A cross-sectional cohort study was conducted to assess the PGVs rate in lung adenocarcinoma patients with a family history of LC, young-onset presentation, history of never/light smoking, or actionable genomic alterations (AGAs). Sequencing was performed using Sophia Hereditary Cancer Solution panel F, including 144 cancer predisposition genes. Variants classified as pathogenic or likely pathogenic were included for further analysis.<BR><B>RESULTS: </B>Of 201 patients, 43 (21.4 %) exhibited PGVs, among which 64.5 % were DNA damage repair genes, and 86.1 % were clinically actionable. The main PGVs were in ATM (9.3 %), TP53 (6.9 %), BRCA2 (6.9 %), and CHEK2 (6.9 %) genes. PGVs were associated with male sex (adjusted odds ratio [aOR] 2.46, 95 % CI 1.15-5.32, p = 0.021), along with a trend toward association with AGAs (aOR 6.04, 95 % CI 0.77-49.74, p = 0.094).<BR><B>CONCLUSIONS: </B>In this study, a high PGVs prevalence was identified based on our selection criteria, which represents an effective strategy to identify candidates for germline genomic testing, potential screening strategies in close relatives, and personalized therapeutic modalities. Our results warrant further exploration in other populations to confirm them.